Smoking history and epidermal growth factor receptor expression as predictors of survival benefit from erlotinib for patients with non–small-cell lung cancer in the …

GM Clark, DM Zborowski, P Santabárbara, K Ding… - Clinical lung cancer, 2006 - Elsevier
Background Erlotinib is an oral, reversible inhibitor of the HER1/epidermal growth factor
receptor (EGFR) tyrosine kinase. A survival advantage for erlotinib compared with placebo …
被引用次数：192 相关文章

Smoking history and epidermal growth factor receptor expression as predictors of survival benefit from erlotinib for patients with non-small-cell lung cancer in the …

GM Clark, DM Zborowski, P Santabarbara… - Clinical Lung …, 2006 - europepmc.org
Background Erlotinib is an oral, reversible inhibitor of the HER1/epidermal growth factor
receptor (EGFR) tyrosine kinase. A survival advantage for erlotinib compared with placebo …

Smoking history and epidermal growth factor receptor expression as predictors of survival benefit from erlotinib for patients with non-small-cell lung cancer in the …

GM Clark, DM Zborowski, P Santabarbara, K Ding… - 2006 - pubmed.ncbi.nlm.nih.gov
Background Erlotinib is an oral, reversible inhibitor of the HER1/epidermal growth factor
receptor (EGFR) tyrosine kinase. A survival advantage for erlotinib compared with placebo …
[PDF] researchgate.net

[PDF][PDF] Smoking History and Epidermal Growth Factor Receptor Expression as Predictors of Survival Benefit from Erlotinib for Patients with Non–Small-Cell Lung …

GM Clark, DM Zborowski, P Santabárbara… - Clinical Lung …, 2006 - researchgate.net
BACKGROUND: Erlotinib is an oral, reversible inhibitor of the HER1/epidermal growth factor
receptor (EGFR) tyrosine kinase. A survival advantage for erlotinib compared with placebo …

Smoking History and Epidermal Growth Factor Receptor Expression as Predictors of Survival Benefit from Erlotinib for Patients with Non–Small-Cell Lung Cancer in …

GM Clark, DM Zborowski… - Clinical Lung …, 2006 - clinical-lung-cancer.com
Background Erlotinib is an oral, reversible inhibitor of the HER1/epidermal growth factor
receptor (EGFR) tyrosine kinase. A survival advantage for erlotinib compared with placebo …

Smoking History and Epidermal Growth Factor Receptor Expression as Predictors of Survival Benefit from Erlotinib for Patients with Non–Small-Cell Lung Cancer in …

GM Clark, DM Zborowski, P Santabárbara, K Ding… - Clinical Lung …, 2006 - infona.pl
Erlotinib is an oral, reversible inhibitor of the HER1/epidermal growth factor receptor (EGFR)
tyrosine kinase. A survival advantage for erlotinib compared with placebo was demonstrated …

Smoking History and Epidermal Growth Factor Receptor Expression as Predictors of Survival Benefit from Erlotinib for Patients with Non–Small-Cell Lung Cancer in …

GM Clark, DM Zborowski, P Santabárbara, K Ding… - Clinical Lung …, 2006 - infona.pl
Erlotinib is an oral, reversible inhibitor of the HER1/epidermal growth factor receptor (EGFR)
tyrosine kinase. A survival advantage for erlotinib compared with placebo was demonstrated …

[引用][C] Smoking history and epidermal growth factor receptor expression as predictors of survival benefit from erlotinib for patients with non-small-cell lung cancer in …

GM CLARK, DM ZBOROWSKI… - Clinical lung …, 2006 - Cancer Information Group